{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-130709","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2025-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.801751+00:00","generated_at":"2026-05-20T06:16:17.805677+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Taysha prices $187M stock offering; TSHA-102 achieves 100% milestone gain, FDA agrees on pivotal trial design","bullets":["Issued 46.9M shares at $2.75/sh and 25.9M pre-funded warrants at $2.749; net proceeds ~$187.4M.","Underwriters granted 30-day option for up to 10.9M additional shares; closing expected May 30.","TSHA-102 in Rett syndrome: 100% (10/10) patients gained/regained ≥1 milestone post-treatment, with high dose outperforming low dose.","FDA provided written alignment on single-arm pivotal Part B trial design; primary endpoint: developmental milestone gain/regain in patients ≥6 yrs.","Astellas option to license TSHA-102 remains exercisable 90 days after receipt of Rett Data Package expected mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-130709","json":"https://secwatch.observer/filing/0001193125-25-130709.json","markdown":"https://secwatch.observer/filing/0001193125-25-130709.md","text":"https://secwatch.observer/filing/0001193125-25-130709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312525130709/0001193125-25-130709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312525130709/d948981d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T06:16:17.805677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}